Average Insider

Where insiders trade, we follow

$GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Healthcare
Sector
Drug Manufacturers - General
Industry
Daniel O'Day
CEO
17600
Employees
$170.26
Current Price
$189.50B
Market Cap
52W Low$116.88
Current$170.2689.4% above low, 10.6% below high
52W High$176.58

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells24$5,289,937.4731,000
2 weeksBuys00--All Sells
Sells38$7,051,374.4241,376
1 monthBuys00--All Sells
Sells517$32,631,800.77188,085
2 monthsBuys00--All Sells
Sells521$35,787,628.27209,085
3 monthsBuys00--All Sells
Sells632$41,560,956.07248,085
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 16, 2026
Mercier Johanna
Chief Comm&Corp Aff Officer
Sale900$171.69$154,517.04View Details
Nov 16, 2026
Mercier Johanna
Chief Comm&Corp Aff Officer
Sale13,922$169.97$2,366,337.65View Details
Nov 16, 2026
Mercier Johanna
Chief Comm&Corp Aff Officer
Sale13,178$171.09$2,254,672.78View Details
Nov 16, 2026
Dickinson Andrew D
Chief Financial Officer
Sale3,000$171.47$514,410.00View Details
Nov 12, 2026
Kramer Kelly A.
Director
Sale200$171.44$34,288.00View Details
Nov 12, 2026
Kramer Kelly A.
Director
Sale1,676$168.23$281,945.94View Details
Nov 12, 2026
Kramer Kelly A.
Director
Sale3,800$169.44$643,880.74View Details
Nov 12, 2026
Kramer Kelly A.
Director
Sale4,700$170.49$801,322.27View Details
Nov 6, 2026
Cain Wettan Keeley M
EVP Gen Counsel, Legal&Comp
Sale3,399$164.11$557,809.89View Details
Nov 5, 2026
O'Day Daniel Patrick
Director
Sale9,810$175.17$1,718,417.70View Details
Nov 4, 2026
O'Day Daniel Patrick
Director
Sale102,619$175.16$17,975,021.11View Details
Nov 2, 2026
O'Day Daniel Patrick
Director
Sale1,600$167.40$267,839.84View Details
Nov 2, 2026
O'Day Daniel Patrick
Director
Sale1,700$168.10$285,771.02View Details
Nov 2, 2026
O'Day Daniel Patrick
Director
Sale1,904$169.27$322,296.36View Details
Oct 30, 2026
O'Day Daniel Patrick
Director
Sale15,881$175.25$2,783,075.37View Details
Nov 2, 2026
O'Day Daniel Patrick
Director
Sale7,796$170.35$1,328,069.65View Details
Nov 2, 2026
O'Day Daniel Patrick
Director
Sale2,000$171.06$342,125.40View Details
Oct 15, 2026
Dickinson Andrew D
Chief Financial Officer
Sale3,000$156.22$468,660.00View Details
Oct 15, 2026
Mercier Johanna
Chief Comm&Corp Aff Officer
Sale3,000$156.22$468,660.00View Details
Oct 1, 2026
O'Day Daniel Patrick
Director
Sale12,000$147.72$1,772,628.00View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Oct 29, 2026
EPS
Estimated$2.15
ActualN/A
Revenue
Estimated$7.78B
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1